Belantamab  (Synonyms: GSK2857914)

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

TNFRSF17/BCMA/CD269

Belantamab (0.000001-10000 μg/mL; 3 days) does not inhibit growth of BCMA-expressing NCI-H929 human multiple myeloma cells or EL4-hBCMA murine lymphoma cells^[2].
Belantamab (0.1-10 μg/mL; 24-72 h) does not induce immunogenic cell death in NCI-H929 human multiple myeloma cells, as measured by ER stress activation, DAMP exposure or release, or reduced cell viability^[2].
Belantamab (10-100 μg/mL; 24-96 h) does not induce immunogenic cell death in EL4-hBCMA murine lymphoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Belantamab (30 mg/kg; i.p.; twice weekly; 3 weeks) drives Fc-dependent (ADCC-mediated) antitumor activity in C57BL/6 mice bearing EL4-hBCMA tumors, though it does not induce complete tumor regressions^[2].
Belantamab (15 mg/kg; i.p.; twice weekly; 3 weeks) does not enhance intratumoral CD8⁺ T-cell infiltration in C57BL/6 mice bearing EL4-hBCMA tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

608  [NCBI]

Q02223

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.06 kDa

2061894-48-0

Liquid

Colorless to light yellow

[Belantamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized BCMA/TNFRSF17 Protein, Human can bind Belantamab. The EC₅₀ for this effect is 8.0 ng/mL.
• 
  Flow Cytometry analysis of K562 cells labelling CD269 (red) with Belantamab (HY-P9980). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Loaded Belantamab on AHC2 biosensor, can bind BCMA/TNFRSF17 Protein, Human (HEK293, His, HY-P72847) with an affinity constant of 3.934E-10 M as determined in BLI assay.

• [1]. Lucijanic M, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Oct 10;391(14):1364.  [Content Brief]

  [2]. Montes de Oca R, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021;20(10):1941-1955.  [Content Brief]